- Home
- MIR vs PTGX Comparison
MIR vs PTGX Comparison
Compare MIR & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIR | PTGX |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | MIR | PTGX |
|---|---|---|
| Price | $24.53 | $94.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | $28.29 | ★ $88.33 |
| AVG Volume (30 Days) | ★ 3.3M | 953.6K |
| Earning Date | 10-28-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.10 | ★ 0.72 |
| Revenue | ★ $902,300,000.00 | $209,217,000.00 |
| Revenue This Year | $8.15 | N/A |
| Revenue Next Year | $19.02 | $296.47 |
| P/E Ratio | $243.04 | ★ $132.39 |
| Revenue Growth | ★ 7.82 | N/A |
| 52 Week Low | $12.00 | $33.70 |
| 52 Week High | $30.28 | $95.39 |
Technical Indicators
Market Signals| Indicator | MIR | PTGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.51 | 70.99 |
| Support Level | $24.52 | $88.30 |
| Resistance Level | $26.36 | $92.80 |
| Average True Range (ATR) | 1.03 | 2.82 |
| MACD | 0.02 | 0.19 |
| Stochastic Oscillator | 31.93 | 94.19 |
Price Performance
Historical ComparisonAbout MIR Mirion Technologies Inc.
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.